data + articles · 7 listed
newest 2016spec sheet11 rows
NPAP is a little-studied member of the PPAP/BPAP family of synthetic 'enhancer' compounds that came out of Jozsef Knoll's work on selegiline (the pharmacologist who first described this drug class). The series shares a 2-propylaminopentane backbone and differs by the aromatic ring at one end: PPAP carries a plain phenyl, BPAP a benzofuran, IPAP an indole, and NPAP a naphthalene (a larger, two-ring aromatic). Enhancers do not force neurotransmitter out of neurons the way stimulants do; they coax catecholaminergic and serotoninergic neurons into releasing a little more dopamine, norepinephrine, and serotonin only when those neurons naturally fire. NPAP itself is barely characterized, so nearly everything that can be said about it is inferred from its better-studied relatives.
- The naphthalene-ring member of the PPAP enhancer family
- Impulse-linked, non-forcing dopaminergic/serotonergic angle
- A genuinely early-research frontier
- Understudied, wide-open space
Mechanism
NPAP is understood as a catecholaminergic and serotoninergic activity enhancer, a mechanism defined by the prototypes of its class because NPAP itself has not been directly characterized [1][4]. An enhancer is not a releasing agent. Instead of emptying the nerve terminal the way amphetamine does, it increases the amount of transmitter released per nerve impulse, so it strengthens a neuron's own signaling only while that neuron is genuinely firing [2][3]. In the class prototypes this raises impulse-linked , , and output in regions such as the substantia nigra, locus coeruleus, and raphe [2].
The structure-activity work behind the series showed that the aromatic ring tunes potency and selectivity; swapping the phenyl of PPAP for a benzofuran is what produced the far more potent BPAP [1]. NPAP carries a naphthalene ring instead, a bulkier two-ring aromatic, so where it sits on that potency curve relative to PPAP and BPAP is a structure-activity question that has not been answered in published work [1]. As with the rest of the family, the molecular target is thought to be the trace amine-associated receptor system, since the endogenous enhancers beta-phenylethylamine and tryptamine are the natural ligands there [5], and the molecule is expected to be carried into neurons by the monoamine transporters, where the benzofuran prototype additionally acts as a mild [6].
Two features carry across the whole class and are worth keeping in mind for NPAP. First, the dose-response is bell-shaped and unusually narrow, appearing in a very low concentration window and fading again at higher doses, so more is emphatically not better [2]. Second, the negative is the active form. Whether NPAP matches the potency, selectivity, or neuroprotective profile of PPAP and BPAP has not been established [1][7].
receptor fingerprint
Impulse-linked catecholamine / releaseenhances (not releases)
TAAR1 (trace amine receptor)agonist (proposed)
Monoamine transporters ( / SERT / NET)substrate; mild reuptake block
Safetyrisks and cautions, not medical advice
NPAP has essentially no human safety data; it is a research-use-only compound. In theory the enhancer mechanism is gentler than a releasing stimulant because it works with your own impulse firing rather than forcing release, but that is animal-model reasoning about the class, not proven safety for NPAP in people. Because it raises monoamine signaling, be cautious about combining it with MAOIs, SSRIs, or other serotonergic or dopaminergic drugs. The narrow, bell-shaped dose-response also makes overshooting easy. Skip it in pregnancy or breastfeeding for lack of data.
Subjective profileweighing the evidence above
Honestly a blank page. It is the naphthalene member of Knoll's enhancer family, and essentially nothing about it is settled in people, so there is nothing to recommend and nothing to rule out. PPAP and BPAP at least have rat literature behind them; this has less than that.
Resources
This entry is here for reference.
Research
- 1996first cited(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants…
- 2016most recentThe significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)
- 1.Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
- 2.(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain
- 3.(-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons
- 4.Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives
- 5.Pharmacological studies with endogenous enhancer substances: beta-phenylethylamine, tryptamine, and their synthetic derivatives
- 6.Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
- 7.The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015)
7 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
How is NPAP different from PPAP, BPAP and IPAP?
Same enhancer backbone, different ring. PPAP has a phenyl, BPAP a benzofuran, IPAP an indole, and NPAP a naphthalene (a bigger two-ring aromatic). In this family the ring changes potency a lot, but NPAP's own numbers aren't published.
Is there human data on NPAP?
No. There's essentially no published research on NPAP specifically, so treat it as a research curiosity rather than an established nootropic; almost everything known is inferred from its relatives.
What does an 'enhancer' actually do?
Instead of dumping transmitter into the synapse like a stimulant, an enhancer makes a neuron release a little more per impulse, and only when it's already firing. That's why the class is described as amplifying your own signaling rather than overriding it.
Why does dose matter so much?
The enhancer effect is bell-shaped and narrow in the prototypes: it shows up at very low amounts and vanishes at higher ones. So with this class, more is not better, and NPAP's exact window isn't known.
Limitations of the evidence
- No human safety data
Notes and cautions
- Bell-shaped, narrow dose-response, so overshooting is easy
- Long-term effects unknown
- Research-chemical purity varies by source